TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03352557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB092
Description: Administered as specified in treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB092
Description: Administered as specified in treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB092
Description: Administered as specified in treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in treatment arm.
Study: NCT00907803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-246 400 mg
Description: Capsules, 400 mg daily for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST-246 600 mg
Description: Capsules, 600 mg daily for 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules, once daily for 14 days
Study: NCT01212497

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation coaching
Description: Participants interact with virtual coach to obtain instruction in mindfulness meditation and coaching support.
Study: NCT03730831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Narrative Exposure Therapy
Description: 8-20 sessions: 1 lifeline session, 6-17 sessions narrative exposure, 1-2 sessions of future-oriented counselling~-\> Intervention is a part of the second work program. First work program focueses on cross-sectional data and includes a systematic record of psychopathology in participants with schizophrenia sepctrum disorder.
Study: NCT01430923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: refrigeration free latanoprost
Description: latanoprost Eye drops 0.005% once daily, 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: latanoprost eye drops
Description: latanoprost eye drops 0.005% w/v, once daily, 3 months
Study: NCT02281474

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nilotinib
Study: NCT01598337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Patients continue their maintenance dose not inturrupted by surgery , 81 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tirofiban
Description: Tirofiban infusion as specified by investigators to start after hemostasis been established

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: Tirofiban infusion as specified by investigators to start after hemostasis been established

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: Tirofiban infusion as specified by investigators to start after hemostasis been established

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirofiban
Description: Tirofiban infusion as specified by investigators to start after hemostasis been established

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 75 mg orally started 6-8hours before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 75 mg orally started 6-8hours before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 75 mg orally started 6-8hours before surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Description: 75 mg orally started 6-8hours before surgery
Study: NCT04423796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted early mobilization
Description: The early mobilization is done by robotic assistance devices.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Early mobilization
Description: Early mobilization by health care professionals without robotic assistance.
Study: NCT01894217

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic testing and reporting for SLCO1B1*5 allele
Description: Blood test for SLCO1B1\*5 allele; reporting of test results to provider and participant
Study: NCT03510052

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Diet Modification Pilot Program (DPM)
Description: Investigator will administer DMP which will include a review of the booklets and any targeted recommendations based on the participant's food and symptom diary. The participant will follow the DMP for 6 weeks and report for a follow-up visit.
Study: NCT01291472

Intervention type: DRUG
Group type: OTHER
Intervention: Ketorolac Tromethamine
Description: After dilution (solution for injection, 10 mg/1ml) in 50-100 ml bag of normal saline drug will be administered by iv bolus, through a peripherally inserted venous catheter, 30 mg, 3 times in one day. The intended duration of administration is 5-10 minutes.
Study: NCT02349516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Squalamine Lactate Ophthalmic Solution 0.2%
Description: Squalamine Lactate Ophthalmic Solution 0.2% eye drop to be administered to study eye either BID or QID for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Squalamine Lactate Ophthalmic Solution 0.2%
Description: Squalamine Lactate Ophthalmic Solution 0.2% eye drop to be administered to study eye either BID or QID for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Squalamine Lactate Ophthalmic Solution 0.2%
Description: Squalamine Lactate Ophthalmic Solution 0.2% eye drop to be administered to study eye either BID or QID for 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Squalamine Lactate Ophthalmic Solution 0.2%
Description: Squalamine Lactate Ophthalmic Solution 0.2% eye drop to be administered to study eye either BID or QID for 52 weeks
Study: NCT00845520

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens implantation +1.00 D postop target
Description: Lens implantation +1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens implantation -1.00 D postop target
Description: Lens implantation -1.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lens implantation 0.00 D postop target
Description: Lens implantation 0.00 D postoperative MRSE target. Light Delivery Device treatment based on postoperative manifest refraction.
Study: NCT02871661

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: Volunteers will take 25 milligrams of this medication every day from their enrollment until completing eight weeks long.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: Volunteers will take 25 milligrams of this medication every day from their enrollment until completing eight weeks long.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: Volunteers will take 25 milligrams of this medication every day from their enrollment until completing eight weeks long.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesiotherapy
Description: Volunteers will be taught to contract their pelvic floor muscles right before stretching it, following a home protocol, every day for eight weeks long.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IC (Quark)
Description: Volunteers will visit physical therapy clinic once a week to receive twenty minutes of electrical stimulation with Interferential Current (Duapex 961 of Quark Medical manufacturer) in their perineal area, for eight weeks long.
Study: NCT01072838

Intervention type: RADIATION
Group type: OTHER
Intervention: APBI (Dose Escalation)
Description: Accelerated, hypofractionated partial breast radiotherapy.~3 dose schemes followed for 6 months each.

Intervention type: DEVICE
Group type: OTHER
Intervention: Contura MLB Breast Brachytherapy Catheter
Study: NCT01180231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxonidine (Physiotens)
Description: Subjects will be asked to take moxonidine, dosage to be determined prior to commencement by a medical doctor for 6 months duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxonidine (Physiotens)
Description: Subjects will be asked to take moxonidine, dosage to be determined prior to commencement by a medical doctor for 6 months duration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Subjects will be asked to follow dietary plans designed by a qualified nutritionist for 6 months.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary intervention
Description: Subjects will be asked to follow dietary plans designed by a qualified nutritionist for 6 months.
Study: NCT03064594

Intervention type: PROCEDURE
Intervention: Cornual pregnancy
Description: we will get the information of operative time, blood loss and postoperative pregnancy and delivery rate.
Study: NCT04617574

Intervention type: DEVICE
Intervention: AEON Endostapler
Description: Surgery with AEON Endostapler

Intervention type: DEVICE
Intervention: Endo GIA Reloads with Tri-Staple Technology
Description: Surgery with Endo GIA Reloads with Tri-Staple Technology
Study: NCT01876966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etravirine
Description: 200 mg ETR b.i.d. from Day 1 to Day 21 with a single 200 mg dose of ETR in the morning on Day 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir
Description: DRV/rtv 600/100 mg b.i.d. from Day 1 to Day 21 with a single dose of DRV/rtv in the morning on Day 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether/lumefantrine
Description: 3 days of treatment with artemether/lumefantrine 80/480 mg (6 doses of 4 tablets \[20/120 mg\] at 0, 8, 24, 36, 48, and 60 hours)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: artemether/lumefantrine
Description: 3 days of treatment with artemether/lumefantrine 80/480 mg (6 doses of 4 tablets \[20/120 mg\] at 0, 8, 24, 36, 48, and 60 hours)
Study: NCT02509858

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thyroxine
Description: treatment with 50μg of thyroxine once daily for two months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thyroxine
Description: treatment with 50μg of thyroxine once daily for two months.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: treatment with 50μg of placebo, once daily, for two months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)
Study: NCT03004625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daclatasvir
Description: to evaluate the treatment efficacy and safety of the drug in HCV patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asunaprevir
Description: to evaluate the treatment efficacy and safety of the drug in HCV patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: to evaluate the treatment efficacy and safety of the drug in HCV patients
Study: NCT02470806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO System
Description: Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: tNPWT System
Description: NPWT from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
Study: NCT00866619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malaria Vaccine 257049
Description: administered intramuscularly into the left deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Malaria Vaccine 257049
Description: administered intramuscularly into the left deltoid.
Study: NCT01598337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: 10 mg daily as per instructions of investigators
Study: NCT00866619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal C Conjugate Vaccine
Description: administered intramuscularly into the left deltoid.
Study: NCT01598337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: 10 mg daily as per instructions of investigators

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: 10 mg daily as per instructions of investigators
Study: NCT00866619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal C Conjugate Vaccine
Description: administered intramuscularly into the left deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal C Conjugate Vaccine
Description: administered intramuscularly into the left deltoid.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal C Conjugate Vaccine
Description: administered intramuscularly into the left deltoid.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cell-culture rabies vaccine
Description: administered intramuscularly into the left deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TritanrixHepB/Hib
Description: administered intramuscularly into the left deltoid.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TritanrixHepB/Hib
Description: administered intramuscularly into the left deltoid.
Study: NCT01285310

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg
Description: 30 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 30mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast 20 mg
Description: 20 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral Placebo tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in active treatment / active treatment extension phase. Participants who are nonresponders will advance early to 20 mg Apremilast BID at Week 16.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Placebo tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in active treatment / active treatment extension phase. Participants who are nonresponders will advance early to 20 mg Apremilast BID at Week 16.
Study: NCT00866619

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin Oral Polio Vaccine (GSK)
Description: administered orally.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polio Sabin Oral Polio Vaccine (GSK)
Description: administered orally.
Study: NCT05120336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagus nerve stimulation
Description: Non-invasive brain stimulation technique that is used to stimulate vagal afferent projections to the nucleus of the solitary tract. Invasive VNS has been approved for the treatment of treatment-resistant depression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagus nerve stimulation
Description: Non-invasive brain stimulation technique that is used to stimulate vagal afferent projections to the nucleus of the solitary tract. Invasive VNS has been approved for the treatment of treatment-resistant depression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagus nerve stimulation
Description: Non-invasive brain stimulation technique that is used to stimulate vagal afferent projections to the nucleus of the solitary tract. Invasive VNS has been approved for the treatment of treatment-resistant depression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcutaneous vagus nerve stimulation
Description: Non-invasive brain stimulation technique that is used to stimulate vagal afferent projections to the nucleus of the solitary tract. Invasive VNS has been approved for the treatment of treatment-resistant depression.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham stimulation
Description: Sham procedure for active transcutaneous vagus nerve stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham stimulation
Description: Sham procedure for active transcutaneous vagus nerve stimulation
Study: NCT01598337

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel
Description: 10 mg daily as per instructions of investigators
Study: NCT03284333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: other
Description: no arm
Study: NCT02609750

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured care & workplace intervention
Description: In addition to structured care a workplace intervention named Convergence Dialogue Meetings (CDM) are carried out. CDM is a three step structured dialogue and meeting model supporting the patient, health care professionals and employer to summarize concrete suggestions to support sustainable work ability and a return to work if sick listed.
Study: NCT05120336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham stimulation
Description: Sham procedure for active transcutaneous vagus nerve stimulation
Study: NCT01694589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDE-225
Description: LDE-225 capsules will be administered as a fixed dose of 800 mg daily for two weeks.
Study: NCT04035681

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem-Solving Therapy
Description: Problem-Solving Therapy is a brief psychosocial intervention for management of depressive symptoms. Participants will have six, one-hour sessions with an interventionist to learn a structured approach to problem-solving.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stroke-Related Health Education
Description: The stroke-related health education program will teach participants about various topics related to stroke. Participants will have six, one-hour sessions with an interventionist to learn about different topics related to stroke.
Study: NCT03030872

Intervention type: DEVICE
Intervention: Investigational software
Description: The study evaluated retrospective de-identified cases that were processed after the imaging procedure had been completed (off-line) using a dedicated workstation.
Study: NCT00536406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BE-ACTIV
Description: BE-ACTIV is 10-week behavioral treatment involving increasing pleasant events.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual (TAU)
Description: TAU includes usual treatment in nursing care facility.
Study: NCT02103764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel
Description: Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medroxyprogesterone acetate
Description: Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
Study: NCT00875212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: calcium glycerophosphate
Description: use of a dentifrice containing CaGP (0.13%) and no fluoride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: no active ingredient
Description: dentifrice without calcium glycerophosphate and no fluoride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluoride
Description: use of a dentifrice containing fluoride (1500ppm) only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAGP + fluoride
Description: calcium glycerophosphate and fluoride dentifrice
Study: NCT03491241

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: hypocaloric diet therapy
Description: all patients will receive an hypocaloric diet, with low carboidrates (\<50%) overload.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: hypocaloric diet therapy
Description: all patients will receive an hypocaloric diet, with low carboidrates (\<50%) overload.
Study: NCT02934932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Comparison of brexpiprazole 2mg to placebo Comparison of brexpiprazole 4mg to placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Comparison of brexpiprazole 2mg to placebo Comparison of brexpiprazole 4mg to placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Brexpiprazole
Description: Comparison of brexpiprazole 2mg to placebo Comparison of brexpiprazole 4mg to placebo
Study: NCT02579915

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FaceAnxiety
Description: Computerized treatment targeting mental habits and primary care linkage.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Symptom Tracking
Description: Weekly self-assessment with validated questionnaires and primary care linkage

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Symptom Tracking
Description: Weekly self-assessment with validated questionnaires and primary care linkage
Study: NCT02176577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Product 0405
Description: Product 0405 will be administered topically, twice daily for 28 days.
Study: NCT03180541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dialectical Behaviour Therapy
Description: Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
Study: NCT03491241

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: hypocaloric diet therapy
Description: all patients will receive an hypocaloric diet, with low carboidrates (\<50%) overload.